Tags

Type your tag names separated by a space and hit enter

Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.

Abstract

PURPOSE

To report on the follow-up of patients who received an intravitreal triamcinolone acetonide injection (IVTA) as treatment of exudative age-related macular degeneration.

METHODS

The clinical interventional case-series study included 205 patients (222 eyes) with progressive exudative age-related macular degeneration with subfoveal neovascularization who consecutively received an IVTA of about 20 mg as only therapeutic procedure and for whom follow-up was at least 3 months. Mean follow-up was 10.4+/-7.1 months (range, 3-35.7 months).

RESULTS

Visual acuity improved significantly (P<0.001) from baseline (0.90+/-0.45 logarithm of the minimum angle of resolution (LogMar)) to a mean minimum of 0.79+/-0.42 LogMar during follow-up. In 86 (38.7%) eyes and in 55 (24.8%) eyes, best visual acuity increased by at least two and three Snellen lines, respectively. Comparing the measurements at specific postinjection examination dates showed that visual acuity measurements taken at 1, 2, and 3 months after injection were not significantly different from the baseline value. Measurements taken at 6, 9, and 12 months after the injection were significantly (P<0.001) lower than the measurements at baseline. Mean loss at 6 months was 1.4+/-3.8 Snellen lines, at 9 months, 2.5+/-4.6 lines, and at 12 months after the injection, 2.6+/-4.0 lines. Intraocular pressure increased significantly (P<0.001) during the first 6 months, and returned to baseline at 9 months after injection.

CONCLUSIONS

Single injection high-dosage IVTA did not show an apparent benefit at 12 months after injection in patients with neovascular age-related macular degeneration.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Mannheim, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de

    , ,

    Source

    Eye (London, England) 21:3 2007 Mar pg 387-94

    MeSH

    Aged
    Aged, 80 and over
    Choroidal Neovascularization
    Glucocorticoids
    Humans
    Injections
    Intraocular Pressure
    Macular Degeneration
    Middle Aged
    Prospective Studies
    Time Factors
    Treatment Outcome
    Triamcinolone Acetonide
    Visual Acuity
    Vitreous Body

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    16410809

    Citation

    Jonas, J B., et al. "Follow-up After Intravitreal Triamcinolone Acetonide for Exudative Age-related Macular Degeneration." Eye (London, England), vol. 21, no. 3, 2007, pp. 387-94.
    Jonas JB, Spandau UH, Kamppeter BA, et al. Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye (Lond). 2007;21(3):387-94.
    Jonas, J. B., Spandau, U. H., Kamppeter, B. A., & Harder, B. (2007). Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye (London, England), 21(3), pp. 387-94.
    Jonas JB, et al. Follow-up After Intravitreal Triamcinolone Acetonide for Exudative Age-related Macular Degeneration. Eye (Lond). 2007;21(3):387-94. PubMed PMID: 16410809.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. AU - Jonas,J B, AU - Spandau,U H, AU - Kamppeter,B A, AU - Harder,B, Y1 - 2006/01/13/ PY - 2006/1/18/pubmed PY - 2007/5/9/medline PY - 2006/1/18/entrez SP - 387 EP - 94 JF - Eye (London, England) JO - Eye (Lond) VL - 21 IS - 3 N2 - PURPOSE: To report on the follow-up of patients who received an intravitreal triamcinolone acetonide injection (IVTA) as treatment of exudative age-related macular degeneration. METHODS: The clinical interventional case-series study included 205 patients (222 eyes) with progressive exudative age-related macular degeneration with subfoveal neovascularization who consecutively received an IVTA of about 20 mg as only therapeutic procedure and for whom follow-up was at least 3 months. Mean follow-up was 10.4+/-7.1 months (range, 3-35.7 months). RESULTS: Visual acuity improved significantly (P<0.001) from baseline (0.90+/-0.45 logarithm of the minimum angle of resolution (LogMar)) to a mean minimum of 0.79+/-0.42 LogMar during follow-up. In 86 (38.7%) eyes and in 55 (24.8%) eyes, best visual acuity increased by at least two and three Snellen lines, respectively. Comparing the measurements at specific postinjection examination dates showed that visual acuity measurements taken at 1, 2, and 3 months after injection were not significantly different from the baseline value. Measurements taken at 6, 9, and 12 months after the injection were significantly (P<0.001) lower than the measurements at baseline. Mean loss at 6 months was 1.4+/-3.8 Snellen lines, at 9 months, 2.5+/-4.6 lines, and at 12 months after the injection, 2.6+/-4.0 lines. Intraocular pressure increased significantly (P<0.001) during the first 6 months, and returned to baseline at 9 months after injection. CONCLUSIONS: Single injection high-dosage IVTA did not show an apparent benefit at 12 months after injection in patients with neovascular age-related macular degeneration. SN - 0950-222X UR - https://www.unboundmedicine.com/medline/citation/16410809/Follow_up_after_intravitreal_triamcinolone_acetonide_for_exudative_age_related_macular_degeneration_ L2 - http://dx.doi.org/10.1038/sj.eye.6702222 DB - PRIME DP - Unbound Medicine ER -